The Motley Fool··Prosper Junior BakinyVertex Pharma's CF Dominance Faces Long-Term Threat From Gene Therapy Rivals
Vertex's cystic fibrosis market dominance faces gene therapy competition post-patent expiration, but patent protection extends through late 2030s while diversification efforts hedge risk.
VRTXKRYSkidney diseasegene therapy